Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Expands By 20.2%

Palisade Bio, Inc. (NASDAQ:PALI) was the target of a significant growth in short interest in February. As of February 13th, there was short interest totaling 25,352,984 shares, a growth of 20.2% from the January 29th total of 21,095,322 shares. Based on an average trading volume of 3,167,745 shares, the days-to-cover ratio is currently 8.0 days. Currently, 17.0% of the shares of the stock are short sold. Currently, 17.0% of the shares of the stock are short sold. Based on an average trading volume of 3,167,745 shares, the days-to-cover ratio is currently 8.0 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC acquired a new stake in Palisade Bio during the fourth quarter worth about $28,318,000. Commodore Capital LP purchased a new stake in shares of Palisade Bio during the 4th quarter worth about $26,896,000. Janus Henderson Group PLC acquired a new stake in Palisade Bio during the 4th quarter worth approximately $24,822,000. RA Capital Management L.P. purchased a new position in Palisade Bio in the fourth quarter valued at approximately $16,742,000. Finally, Eversept Partners LP acquired a new position in Palisade Bio during the fourth quarter valued at approximately $12,670,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Palisade Bio Price Performance

PALI stock traded down $0.04 on Thursday, hitting $1.70. 554,589 shares of the company were exchanged, compared to its average volume of 4,395,729. The stock has a market capitalization of $253.30 million, a price-to-earnings ratio of -0.80 and a beta of 1.53. The business’s fifty day moving average is $1.84 and its two-hundred day moving average is $1.61. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.64.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Citigroup reissued a “buy” rating on shares of Palisade Bio in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Thursday, January 22nd. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Finally, Piper Sandler assumed coverage on shares of Palisade Bio in a research note on Monday, December 29th. They issued an “overweight” rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $13.25.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.